Novel anti-infective treatments

Xellia is a specialty pharmaceutical company focusing on providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions.

About us

Enhancing patient care and improving convenience

Our innovation is focused on enhancing patient care and improving convenience and ease of use for healthcare professionals based on improved formulations, specialty pharmaceutical dosage forms and more convenient administration paradigms of anti-infective products.

Science and innovation

Leading global, vertically integrated, supplier of important anti-infectives

We are the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). We manufacture and supply Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) to over 500 pharmaceutical companies across 80 countries.

Our range of products

Featured news

17 Jun 2024

Xellia Pharmaceuticals to focus on the manufacturing and commercialization of its life-saving anti-infectives portfolio through its global B2B partners

Read article
29 Apr 2024

US Court Lifts Modified Consent Decree Entered into by FDA and Xellia’s Cleveland Facility

Read article

Xellia’s goal is to demonstrate excellence in innovative development and state-of-the-art manufacturing to meet the demands for anti-infective and critical care therapies for patients around the world

Who we are

Xellia is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability.

Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals.